Antyra, Inc. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 23

Antyra, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Antyra, Inc. - Product Pipeline Review - 2012” provides data on the Antyra, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Antyra, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Antyra, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Antyra, Inc. - Brief Antyra, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Antyra, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Antyra, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Antyra, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Antyra, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Antyra, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antyra, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antyra, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antyra, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Antyra, Inc.; Antyra, Inc. - Key Therapeutics; Antyra, Inc. - Pipeline Overview and Promising Molecules; Antyra, Inc. - News; Antyra, Inc. - Latest Updates; Antyra, Inc. - Pipeline; Antyra, Inc. - Discontinued/Dormant Projects

2
List of Tables 3
List of Figures 3
Antyra, Inc. Snapshot 4
Antyra, Inc. Overview 4
Key Information 4
Key Facts 4
Antyra, Inc. – Research and Development Overview 5
Key Therapeutic Areas 5
Antyra, Inc. – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Antyra, Inc. – Pipeline Products Glance 9
Antyra, Inc. – Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Antyra, Inc. – Drug Profiles 11
ANT-429 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
ANT-C7 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
ANT-G12 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
EPO Mimetics 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Antyra, Inc. – Pipeline Analysis 15
Antyra, Inc. – Pipeline Products by Therapeutic Class 15
Antyra, Inc. – Pipeline Products By Target 16
Antyra, Inc. – Pipeline Products By Mechanism of Action 17
Antyra, Inc. – Locations And Subsidiaries 18
Head Office 18
Financial Deals Landscape 19
Antyra, Inc., Deals Summary 19
Antyra, Inc., Pharmaceuticals & Healthcare, Deal Details 20
Licensing Agreements 20
Antyra Enters Into Licensing Agreement With Novo Nordisk 20
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables
Antyra, Inc., Key Information 4
Antyra, Inc., Key Facts 4
Antyra, Inc. – Pipeline by Indication, 2012 6
Antyra, Inc. – Pipeline by Stage of Development, 2012 7
Antyra, Inc. – Monotherapy Products in Pipeline, 2012 8
Antyra, Inc. – Pre-Clinical, 2012 9
Antyra, Inc. – Discovery, 2012 10
Antyra, Inc. – Pipeline By Therapeutic Class, 2012 15
Antyra, Inc. - Pipeline By Target, 2012 16
Antyra, Inc. – Pipeline Products By Mechanism of Action, 2012 17
Antyra, Inc., Deals Summary 19
Antyra Enters Into Licensing Agreement With Novo Nordisk 20

List of Figures
Antyra, Inc. – Pipeline by Indication, 2012 6
Antyra, Inc. – Pipeline by Stage of Development, 2012 7
Antyra, Inc. – Monotherapy Products in Pipeline, 2012 8
Antyra, Inc. – Pipeline By Therapeutic Class, 2012 15
Antyra, Inc. - Pipeline By Target, 2012 16
Antyra, Inc. - Pipeline Products By Mechanism of Action, 2012 17

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Analysis of Google Inc